Finotti Alessia


Responsabile dell'U.O.

Cognome e Nome

Finotti Alessia

Qualifica

PA

Dipartimento

Scienze della Vita e Biotecnologie

Settore scientifico disciplinare

BIO/10

E-mail

alessia.finotti@unife.it

Telefono

0532-974510

Personale strutturato

Cognome e Nome

Ferrari Davide

Qualifica

PA

Dipartimento

Scienze della Vita e Biotecnologie

Ente di appartenenza

Università di Ferrara

Cognome e Nome

Ferraresi Paolo

Qualifica

Technician

Dipartimento

Scienze della Vita e Biotecnologie

Ente di appartenenza

Università di Ferrara

Cognome e Nome

Gambari Roberto

Qualifica

Professore emerito

Dipartimento

Scienze della Vita e Biotecnologie

Ente di appartenenza

Università di Ferrara

Personale non strutturato

Cognome e Nome

Zuccato Cristina

Qualifica

Assegnista

Dipartimento

Scienze della Vita e Biotecnologie

Ente di appartenenza

Università di Ferrara

Cognome e Nome

Gasparello Jessica

Qualifica

Borsista

Dipartimento

Scienze della Vita e Biotecnologie

Ente di appartenenza

Università di Ferrara

Cognome e Nome

Cosenza Lucia Carmela

Qualifica

Assegnista

Dipartimento

Scienze della Vita e Biotecnologie

Ente di appartenenza

Università di Ferrara

Cognome e Nome

Zurlo Matteo

Qualifica

Borsista

Dipartimento

Scienze della Vita e Biotecnologie

Ente di appartenenza

Università di Ferrara

Cognome e Nome

Papi Chiara

Qualifica

Ph.D student

Dipartimento

Scienze della Vita e Biotecnologie

Ente di appartenenza

Università di Ferrara

Linee di ricerca

-Targeting of the microRNA/transcription factor network combined with a PNA-based antisense approach for SARS-CoV-2 for tackling viral expression and the cytokine storm of COVID-19. -Gene editing in β-thalassemia, Shwachman-Diamond Syndrome and cystic fibrosis. -Drug repurposing in β-thalassemia and cystic fibrosis as a useful strategy to develop sustainable therapeutic approaches for rare diseases. -From laboratory research to “orphan drug designation” for β-thalassemia and cystic fibrosis. -Ex vivo and in vivo effects of Sirolimus in β-thalassemia: from pre-clinical research to clinical trials. -Prediction of the disease severity and the clinical outcome by studying fetal haemoglobin related BCL11A, MYB, LYAR and XmnI polymorphisms in β-thalassemia. -Targeting BCL11A for gamma-globin mRNA induction in erythroid precursor cells from β-thalassemia patients. -Identification of novel compounds as inducers of erythroid differentiation for the development of therapeutic protocols for β-thalassemia. -Development, characterization and maintenance of cellular biobanks for β-thalassemia. -Study of microRNAs involved in human genetic pathologies for the development of new approaches of microRNA targeting and miRNA replacement. -MicroRNA therapeutics for the development of protocols aimed at the rescue of CFTR biological activity in cystic fibrosis cells: increase CFTR expression by peptide-nucleic acid targeting microRNAs regulators of CFTR and NHERF1. -Development of novel therapeutic strategies using microRNA and combined approaches in oncology. -Novel strategies for the delivery of miRNAs and PNAs: calixarenes. -Induction of apoptosis temozolomide-resistant glioma cell lines using combined approaches. -Studies on the relationship between transcription factors and microRNA expression in cystic fibrosis. -Development of a Peptide Nucleic Acid (PNA)-based strategy to inhibit proliferation and anti-inflammatory activity of Pseudomonas aeruginosa. -Molecular analysis of peripheral blood (liquid biopsy) biomarkers (circulating microRNAs) in cancer patients. -Proteomics and transcriptomics (microRNA and mRNA NGS) analysis in genetic diseases (cystic fibrosis, β-thalassemia, Shwachman-Diamond Syndrome) and in neoplastic pathologies (glioblastoma, colon cancer).

Tecnologie in uso dall'UO

  1. 1.
    Procaryotic and eukaryotic cell cultures
  2. 2.
    Primary mammalian cell cultures
  3. 3.
    Genome editing with CRISPR-Cas9
  4. 4.
    Reporter gene assays
  5. 5.
    Secretomic Analysis
  6. 6.
    Nucleic acid quantification: qRT-PCR, ddPCR
  7. 7.
    Flow cytometry
  8. 8.
    Microscopy and Live Cell Screening Systems
  9. 9.
    SPR technology
  10. 10.
    HPLC

Strumentazione

Denominazione

BioStation Model Cell-S1
Biacore-X100
HPLC System Gold 166-Detector and 126-Solvent Module

Struttura ove la strumentazione è allocata

SVEB
SVEB
SVEB

Responsabile

Alessia Finotti
Roberto Gambari/Alessia finotti
Alessia Finotti

Pubblicazioni

  1. 1.
    Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein. Gasparello J, D'Aversa E, Papi C, Gambari L, Grigolo B, Borgatti M, Finotti A, Gambari R. Phytomedicine. 2021 May 4;87:153583. doi: 10.1016/j.phymed.2021.153583.
  2. 2.
    Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β039-thalassemia patients. Cosenza LC, Gasparello J, Romanini N, Zurlo M, Zuccato C, Gambari R, Finotti A. Mol Ther Methods Clin Dev. 2021 Apr 3;21:507-523. doi: 10.1016/j.omtm.2021.03.025. eCollection 2021
  3. 3.
    Delivery of Peptide Nucleic Acids Using an Argininocalix[4]arene as Vector. Finotti A, Gasparello J, Casnati A, Corradini R, Gambari R, Sansone F. Methods Mol Biol. 2021;2211:123-143. doi: 10.1007/978-1-0716-0943-9_10.
  4. 4.
    reatment of human airway epithelial Calu-3 cells with a peptide-nucleic acid (PNA) targeting the microRNA miR-101-3p is associated with increased expression of the cystic fibrosis Transmembrane Conductance Regulator (CFTR) gene. Fabbri E, Tamanini A, Jakova T, Gasparello J, Manicardi A, Corradini R, Finotti A, Borgatti M, Lampronti I, Munari S, Dechecchi MC, Cabrini G, Gambari R. Eur J Med Chem. 2021 Jan 1;209:112876. doi: 10.1016/j.ejmech.2020.112876.
  5. 5.
    A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery. Gasparello J, Papi C, Allegretti M, Giordani E, Carboni F, Zazza S, Pescarmona E, Romania P, Giacomini P, Scapoli C, Gambari R, Finotti A. Cancers (Basel). 2020 Aug 25;12(9):2410. doi: 10.3390/cancers12092410.
  6. 6.
    High Levels of Apoptosis Are Induced in the Human Colon Cancer HT-29 Cell Line by Co-Administration of Sulforaphane and a Peptide Nucleic Acid Targeting miR-15b-5p. Gasparello J, Gambari L, Papi C, Rozzi A, Manicardi A, Corradini R, Gambari R, Finotti A. Nucleic Acid Ther. 2020 Jun;30(3):164-174. doi: 10.1089/nat.2019.0825.
  7. 7.
    BCL11A mRNA Targeting by miR-210: A Possible Network Regulating γ-Globin Gene Expression. Gasparello J, Fabbri E, Bianchi N, Breveglieri G, Zuccato C, Borgatti M, Gambari R, Finotti A. Int J Mol Sci. 2017 Nov 26;18(12):2530
  8. 8.
    Purinergic Signaling in Controlling Macrophage and T Cell Functions During Atherosclerosis Development. Ferrari D, la Sala A, Milani D, Celeghini C, Casciano F. Front Immunol. 2021 Feb 16;11:617804. doi: 10.3389/fimmu.2020.617804
  9. 9.
    Is there a link between vitamin D status, SARS-CoV-2 infection risk and COVID-19 severity? Ferrari D, Locatelli M, Briguglio M, Lombardi G. Cell Biochem Funct. 2021 Jan;39(1):35-47. doi: 10.1002/cbf.3597
  10. 10.
    Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency. Ferraresi P, Balestra D, Guittard C, Buthiau D, Pan-Petesh B, Maestri I, Farah R, Pinotti M, Giansily-Blaizot M. Haematologica. 2020 Mar;105(3):829-837. doi: 10.3324/haematol.2019.217539.

Dottorati di ricerca

Componente UO

Alessia Finotti

Dottorato di ricerca

Scienze Biomediche e Biotecnologiche

Coordinatore

Prof. Pinton Paolo

Sede

ferrara